Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

9.60
-0.2200-2.24%
Volume:437.95K
Turnover:4.18M
Market Cap:734.58M
PE:-6.67
High:9.71
Open:9.66
Low:9.45
Close:9.82
52wk High:14.00
52wk Low:4.35
Shares:76.52M
Float Shares:60.06M
Volume Ratio:0.85
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4390
EPS(LYR):-0.7210
ROE:-81.84%
ROA:-28.64%
PB:5.82
PE(LYR):-13.32

Loading ...

Press Release: Candel Therapeutics Appoints Martine Zimmermann, PharmD, to Its Board of Directors

Dow Jones
·
Sep 10

Candel Therapeutics Highlights Progress of Lead Oncology Candidate

TIPRANKS
·
Sep 10

Candel Therapeutics Grants 31,400 Inducement Stock Options at $13.07 Per Share

Reuters
·
Sep 02

Candel Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 02

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 02

Candel Therapeutics CEO to Speak at Citi Biopharma Back to School Conference Fireside Chat

Reuters
·
Aug 26

Candel Therapeutics to Present at September Investor Conferences

GlobeNewswire
·
Aug 26

Has Candel Therapeutics (CADL) Run Too Far Ahead On Widening Losses?

Simply Wall St.
·
Aug 24

Candel Therapeutics CTO Seshu Tyagarajan Sells 7,000 Shares for $84,000

Reuters
·
Aug 20

Candel Therapeutics is Maintained at Neutral by B of a Securities

Dow Jones
·
Aug 15

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP)

TIPRANKS
·
Aug 14

BofA Adjusts Price Target on Candel Therapeutics to $12 From $9

MT Newswires Live
·
Aug 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)

TIPRANKS
·
Aug 14

Candel Therapeutics Price Target Maintained with a $23.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 14

Candel Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss

MT Newswires Live
·
Aug 13

Candel Therapeutics: Q2 EPS $-0.52

THOMSON REUTERS
·
Aug 13

Candel Therapeutics Q2 FY26 Net Loss Widens to $38.9 Million; R&D Expense More than Doubles to $19.8 Million

Reuters
·
Aug 13

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

THOMSON REUTERS
·
Aug 13

Candel Therapeutics Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview

Reuters
·
Aug 10